Insider Selling: Omada Health (NASDAQ:OMDA) CEO Sells $283,160.00 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 14,158 shares of Omada Health stock in a transaction on Friday, June 26th. The shares were sold at an average price of $20.00, for a total value of $283,160.00. Following the completion of the transaction, the chief executive officer owned 394,603 shares in the company, valued at $7,892,060. The trade was a 3.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Omada Health Price Performance

Shares of NASDAQ:OMDA opened at $20.89 on Monday. The firm has a market capitalization of $1.24 billion and a PE ratio of -77.37. The business has a 50-day moving average of $16.51 and a two-hundred day moving average of $14.84. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%.The business had revenue of $78.05 million for the quarter. As a group, research analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Hedge Funds Weigh In On Omada Health

A number of institutional investors have recently added to or reduced their stakes in OMDA. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Omada Health in the fourth quarter worth about $1,222,000. Divisadero Street Capital Management LP acquired a new stake in Omada Health during the 3rd quarter valued at approximately $30,510,000. a16z Perennial Management L.P. purchased a new stake in Omada Health during the 4th quarter worth approximately $2,480,000. Madryn Asset Management LP purchased a new stake in Omada Health during the 4th quarter worth approximately $9,212,000. Finally, Independent Advisor Alliance acquired a new position in shares of Omada Health in the 4th quarter valued at approximately $717,000.

Wall Street Analyst Weigh In

OMDA has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Omada Health in a research note on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on shares of Omada Health in a report on Friday, May 8th. JPMorgan Chase & Co. lowered their price target on Omada Health from $32.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, March 12th. Weiss Ratings raised Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Citigroup restated an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.91.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.